| Fatima Eslami-varzaneh, MD | |
|
200 Watson Boulvard, Stratford, CT 06615 | |
| (203) 380-4183 | |
| Not Available |
| Full Name | Fatima Eslami-varzaneh |
|---|---|
| Gender | Female |
| Speciality | Pathology - Anatomic Pathology |
| Location | 200 Watson Boulvard, Stratford, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558488213 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0101X | Pathology - Anatomic Pathology | 042185 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Fatima Eslami-varzaneh, MD 103 Secret Hollow Rd, Monroe, CT 06468-1289 Ph: (203) 452-9774 | Fatima Eslami-varzaneh, MD 200 Watson Boulvard, Stratford, CT 06615 Ph: (203) 380-4183 |
News Archive
Since the start of the COVID-19 pandemic, thousands of Americans have had to delay recommended but elective orthopedic surgical procedures, such as joint replacement surgery or knee arthroscopy.
Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston.
A skin cancer prevention program called SunSmart may have contributed to a recent reduction in melanoma among younger residents of Melbourne, according to a study published October 8 in the open-access journal PLOS Medicine by Suzanne Dobbinson of Cancer Council Victoria in Australia, and colleagues.
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
In a step forward in the push for targeted treatments that can block the specific molecular malfunctions driving cancer, University of North Carolina Lineberger Comprehensive Cancer Center researchers have demonstrated how a genetic mutation can drive the most common type of lymphoma as well as melanoma, the deadliest form of skin cancer.
› Verified 9 days ago
Dr. Nada Y Alsaigh, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 200 Watson Blvd, Stratford, CT 06615 Phone: 203-380-4112 | |
Dr. Suha H Mishalani, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 200 Watson Blvd, Stratford, CT 06615 Phone: 203-381-4000 | |
Patricia Dargis Beliveau, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 200 Watson Blvd, Stratford, CT 06615 Phone: 203-381-4000 | |
Dr. Adam James Carter, D.O. Pathology Medicare: Not Enrolled in Medicare Practice Location: 200 Watson Blvd, Stratford, CT 06615 Phone: 203-380-4563 | |
Dr. Glenn H Segal, D.O. Pathology Medicare: Medicare Enrolled Practice Location: 200 Watson Blvd, Stratford, CT 06615 Phone: 203-380-4585 | |
Dr. James Burns Amberson, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 200 Watson Blvd, Stratford, CT 06615 Phone: 203-381-4058 |